Kailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $16.75 and last traded at $16.76, with a volume of 311398 shares changing hands. The stock had previously closed at $17.48.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on KLRA. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Zacks Research raised Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. William Blair assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Evercore initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Leerink Partners began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Down 4.2%

The firm’s fifty day simple moving average is $20.43. The firm has a market capitalization of $2.17 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its earnings results on Tuesday, May 26th. The company reported ($3,650.00) EPS for the quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.